Novo Nordisk raises expectations for Eli Lilly after CagriSema slipup
by
Contributor since / Followers
Contributor since / Followers
23 hours ago
CR Novo Nordisk (NVO) and Eli Lilly (LLY), the undisputed leaders in the global obesity
LLY
Eli Lilly’s Zepbound gains sleep apnea indication
by
Contributor since / Followers
Contributor since / Followers
2 days ago
NicolasMcComber/iStock via Getty Images The U.S. FDA has approved an additional indication for Eli Lilly’s
Pfizer gets FDA accelerated approval for Braftovi
by
Contributor since / Followers
Contributor since / Followers
2 days ago
Alexandros Michailidis Pfizer (NYSE:PFE) has received FDA accelerated approval for its drug Braftovi in combination
Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now
by ONeil Trader
Contributor since 2012 / 8920 Followers
Contributor since 2012 / 8920 Followers
2 days ago
Summary: The updates from clinical trials of Eli Lilly’s competitors in the obesity market were
J.P. Morgan’s top Healthcare stocks for 2025
by
Contributor since / Followers
Contributor since / Followers
2 days ago
gorodenkoff/iStock via Getty Images J.P. Morgan’s U.S. equity analysts picked their top stocks for 2025,
Why is Novo Nordisk crashing after data for next-gen weight loss drug?
by
Contributor since / Followers
Contributor since / Followers
2 days ago
JHVEPhoto/iStock Editorial via Getty Images Novo Nordisk (NVO) plunged to a 52-week low on Friday
Novo Nordisk crashes after data for next gen obesity drug, Eli Lilly spikes
by
Contributor since / Followers
Contributor since / Followers
2 days ago
hapabapa/iStock Editorial via Getty Images Novo Nordisk (NVO) shares crashed on Friday, while its rival
Biggest stock movers Friday: FDX, X and more
by
Contributor since / Followers
Contributor since / Followers
2 days ago
Jonathan Kitchen Stock futures slipped during Friday’s premarket session as investors eagerly awaited the release
Hims & Hers Health falls as FDA issues unfavorable compounded GLP-1 decision
by
Contributor since / Followers
Contributor since / Followers
3 days ago
aprott/iStock via Getty Images Hims & Hers Health (NYSE:HIMS) is down 7% in early morning
Zealand Pharma And Eli Lilly: Strategic Focus On Weight Management And Future Outlook
by BioCGT Investor
Contributor since 2024 / 645 Followers
Contributor since 2024 / 645 Followers
3 days ago
Summary: Eli Lilly’s diverse product portfolio and promising pipeline, including Tirzepatide, Orforglipron, and Retatrutide, support